Association between gestational age at birth, antenatal corticosteroids, and outcomes at 5 years: multiple courses of antenatal corticosteroids for preterm birth study at 5 years of age (MACS-5)
Authors:
- Elizabeth AsztalosElizabeth Asztalos
- Andrew WillanAWAndrew Willan
- Kellie MurphyKMKellie Murphy
- Stephen MatthewsSMStephen Matthews
- Arne OhlssonAOArne Ohlsson
- Saroj SaigalSSSaroj Saigal
- Anthony ArmsonAAAnthony Armson
- Edmond KellyEKEdmond Kelly
- Marie-France DelisleMDMarie-France Delisle
- Amiram GafniAGAmiram Gafni
- Shoo LeeSLShoo Lee
- Renee SananesRSRenee Sananes
Open Access
- 13 August 2014
- journal article
- research article
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 14 (1) , 1-8
Abstract
The Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study (MACS) showed no benefit in the reduction of major neonatal mortality/morbidity or neurodevelopment at 2 and 5 years of age. Using the data from the randomized controlled trial and its follow-up, the aim of this study was to evaluate the association between gestational ages at birth in children exposed to single versus multiple courses of antenatal corticosteroid (ACS) therapy in utero and outcomes at 5 years of age. A total of 1719 children, with the breakdown into groupings of <30, 30–36, and ≥ 37 weeks gestation at birth, contributed to the primary outcome: death or survival with a disability in one of the following domains: neuromotor, neurosensory, and neurobehavioral/emotional disability and were included in this analysis. Gestational age at birth was strongly associated with the primary outcome, p < 0.001. Overall, the interaction between ACS groups and gestational age at birth was not significant, p = 0.064. Specifically, in the 2 preterm categories, there was no difference in the primary outcome between single vs. multiple ACS therapy. However, for infants born ≥37 weeks gestation, there was a statistically significant increase in the risk of the primary outcome in multiple ACS therapy, 48/213 (22.5%) compared to 38/249 (15.3%) in the single ACS therapy; OR = 1.69 [95% CI: 1.04, 2.77]; p = 0.037. Preterm birth (<37 weeks gestation) remained the primary factor contributing to an adverse outcome regardless of the number of courses of ACS therapy. Children born ≥ 37 weeks and exposed to multiple ACS therapy may have an increased risk of neurodevelopmental/neurosensory impairment by 5 years of age. To optimize outcomes for infants/children, efforts in reducing the incidence of preterm birth should remain the primary focus in perinatal research. This study has been registered at (identifier NCT00187382 )Keywords
This publication has 15 references indexed in Scilit:
- Multiple Courses of Antenatal Corticosteroids for Preterm Birth StudyJAMA Pediatrics, 2013
- Effects of antenatal corticosteroids on the hypothalamic-pituitary-adrenocortical axis of the fetus and newborn: experimental findings and clinical considerationsAmerican Journal of Obstetrics and Gynecology, 2012
- Repeated antenatal corticosteroid treatments adversely affect neural transmission time and auditory thresholds in laboratory ratsNeurotoxicology and Teratology, 2012
- Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study: 2-Year OutcomesPediatrics, 2010
- Effect of prenatal glucocorticoid treatment on size at birth among infants born at term gestationJournal of Perinatology, 2009
- Neurodevelopmental Outcome of Extremely Low Birth Weight Infants Randomly Assigned to Restrictive or Liberal Hemoglobin Thresholds for Blood TransfusionPediatrics, 2009
- Caffeine Therapy for Apnea of PrematurityNew England Journal of Medicine, 2006
- Long-Term Effects of Indomethacin Prophylaxis in Extremely-Low-Birth-Weight InfantsNew England Journal of Medicine, 2001
- Retinal maturation is delayed by repeated, but not single, maternal injections of betamethasone in sheepEye, 2000
- ABC of labour care: Preterm labour and premature rupture of membranesBMJ, 1999